Other · developed by Protalix
OPRX-106 is an orally delivered, once-daily agent studied in ulcerative colitis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02768974 | Phase 2 | Ulcerative Colitis | Unknown | PLX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Ulcerative Colitis
Updated Oct 25, 2026. Something wrong or missing? Report it on the PLX page.
See PLX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PLX catalysts and pipeline →